RedHill Biopharma Announces Positive Top-Line Results from Phase III Study of RHB-104 in Crohn’s Disease

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/12/2026

1. ADBE
2. SPCX
3. USO
4. SPY
5. RH
6. NVDA
7. RKLB
8. CRM
9. MSFT
10. DOL:CN

Go back to RedHill Biopharma Announces Positive Top-Line Results from Phase III Study of RHB-104 in Crohn’s Disease

Redhill Biopharma (RDHL) PT Raised to $28 at Nomura/Instinet

July 30, 2018 1:00 PM EDT

Nomura/Instinet raised its price target on Redhill Biopharma (NASDAQ: RDHL) to $28.00 (from $18.00) while maintaining a Buy rating following positive RHB-104 results.

Analyst Christopher Marai note management indicated that a 16-week time-point measure is a reasonable endpoint, but they will await... More